Market revenue in 2022 | USD 31.2 million |
Market revenue in 2030 | USD 100.3 million |
Growth rate | 15.7% (CAGR from 2022 to 2030) |
Largest segment | Gene panel, ldt & others |
Fastest growing segment | Gene Panel, LDT & Others |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Gene Panel, LDT & Others |
Key market players worldwide | Illumina Inc, Exact Sciences Corp, Foundation Medicine, Guardant Health Inc, Burning Rock Biotech Ltd ADR, Freenome, AnchorDx, GeneCast, Elypta |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to multi cancer early detection market will help companies and investors design strategic landscapes.
Gene panel, ldt & others was the largest segment with a revenue share of 100% in 2022. Horizon Databook has segmented the Canada multi cancer early detection market based on gene panel, ldt & others covering the revenue growth of each sub-segment from 2018 to 2030.
Canada’s market is expected to grow lucratively over the forecast period and follows the U.S. in the adoption of MCED tests, as FDA-approved tests are permitted for use in the country. In contrast to conventional cancer screening programs, emerging health technologies that use liquid biopsy techniques for the early diagnosis of cancer may present a fresh strategy.
These tests may aid in lowering some of the obstacles related to conventional screening tests and extending the reach of screening beyond specific cancers. Emerging MCED technologies include the Galleri Test (GRAIL) and Cancer SEEK (Exact Sciences Corporation), which use NGS, computational algorithms with AI, and molecular analysis of blood samples to detect signs of various cancers.
According to the Canadian Journal of Health Technologies, more than 80,000 deaths occur in Canada each year due to cancer, which is a leading cause of death. In Canada, early identification of cancer is a strategic health priority.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada multi cancer early detection market , including forecasts for subscribers. This country databook contains high-level insights into Canada multi cancer early detection market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account